Efficacy of 51Cr-EDTA clearance to tailor a carboplatin therapeutic regimen in ovarian cancer patients.

Abstract

AIM:

The aim of this study was to evaluate the efficacy of 51Cr-EDTA clearance to tailor the carboplatin dose in two different therapeutic regimens of advanced epithelial ovarian cancer.

MATERIALS AND METHODS:

14 patients entered the study, eight treated by carboplatin (C) alone and six by C and paclitaxel (P). The dose of C was calculated from the Calvert formula [DOSE(mg) = desired AUC x (GFR + 25)] based on the Glomerular filtration rate (GFR) figure; in our protocol desired Area under the curve (AUC) figure was 5 mg/ml x min. The method used to calculate the GFR requires only 4 blood samples taken in the late part of the disappearance plasmatic curve and conjugates accuracy to an acceptable clinical compliance.

RESULTS:

In only 5 courses a significant hematological toxicity (HT) was present (4 courses grade 2, 1 course grade 3); it was necessary to delay only 2 courses; no treatment was discontinued because of HT.

CONCLUSION:

We concluded that there is no summation toxicity of C and P if administered simultaneously and that the assessment of GFR by 51Cr-EDTA clearance is an optimal tool to predict an acceptable toxicity.

• Authors: G Martino, V Frusciante, A Varraso, F Barbano, A Capotorto, F Dicembrino, F Petruzzelli, G Rubini
• Journal: Anticancer research (Anticancer Res) 1999 Nov-Dec Vol. 19 Issue 6C Pg. 5587-91 ISSN: 0250-7005 [Print] Greece
• PMID: 10697623 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Antineoplastic Agents
• Antineoplastic Agents, Phytogenic
• Chelating Agents
• Chromium Radioisotopes
• Edetic Acid
• Carboplatin
• Paclitaxel

Topics

• Adult
• Aged
• Antineoplastic Agents (therapeutic use)
• Antineoplastic Agents, Phytogenic (therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Carboplatin (therapeutic use)
• Chelating Agents (pharmacokinetics)
• Chromium Radioisotopes
• Edetic Acid (pharmacokinetics)
• Female
• Glomerular Filtration Rate
• Humans
• Metabolic Clearance Rate
• Middle Aged
• Ovarian Neoplasms (drug therapy, metabolism)
• Paclitaxel (therapeutic use)